Neptune Technologies & Bioresources (NEPT)
Neptune Technologies & Bioresources Revenue Growth: 15.64%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
NEPT Revenue Growth Rankings
| Overall | 70th percentile | 1295 of 4364 |
| Sector | 63rd percentile | 166 of 456 in Healthcare |
| Industry | 53rd percentile | 58 of 126 in Biotechnology |
NEPT Revenue Growth Range, Past 5 Years
| Minimum | -11.53% | Feb 2011 |
| Maximum | 200.3% | Aug 2010 |
| Average | 38.99% |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
You may also be interested in these NEPT related companies
NEPT News
Trading Radar for 05/31: Ciena (CIEN), Joy Global (JOY), RealD (RLD), Splunk (SPLK), Omnivision (OVTI) Report
May 30, 5:22PM Street Insider
May 30, 5:22PM Street Insider
4 breakout: $NEPT. Not much in the four stocks on offer. No penny stocks, but nothing over $10 either.
about 4 days ago by fallondpicks
about 4 days ago by fallondpicks
Elan Corporation plc, Quest Software Among Stocks Up on High Volume Friday
May 25, 12:33PM Fox Business
May 25, 12:33PM Fox Business
$NEPT http://stks.co/3z7g Breakout Watch: NEPT
see video here: http://stks.co/3z7h
about 6 days ago by MarketScanners
about 6 days ago by MarketScanners
Equity Briefing: ROTH Capital sees NEPT stock poised for significant growth this year
May 23, 8:57AM Thomson Reuters ONE
May 23, 8:57AM Thomson Reuters ONE
Neptune Believes the Australian Patent Office Will Reconsider Its Grant of Aker's Australian Patent
May 22, 3:00AM GlobeNewswire
May 22, 3:00AM GlobeNewswire
Neptune, the Only Krill Oil Manufacturer Certified as "Friend of the Sea"
May 22, 3:00AM GlobeNewswire
May 22, 3:00AM GlobeNewswire
$NEPT 200 Day SMA Cross - Price crossed above 200 day SMA (2.9486). Confirmed by volume.
about 9 days ago by TradeIdeasQuant
about 9 days ago by TradeIdeasQuant
Equity Briefing: NFL's John Elway scheduled to pitch Neptune during CNBC and Fox Business News interviews
May 10, 4:16PM Thomson Reuters ONE
May 10, 4:16PM Thomson Reuters ONE
RT @HowardGroup - NFL Legend & $NEPT Ambassador John Elway Heading to New York Natural Health Products Conference http://stks.co/3iD6
about 23 days ago by epime7heus
about 23 days ago by epime7heus
NKO(R) Ambassador John Elway to Speak at SupplySide MarketPlace (NYC) and to Visit Neptune's Booth
May 03, 8:00AM GlobeNewswire
May 03, 8:00AM GlobeNewswire
RT @dondet $NEPT my most worrisome prob w/this stock is that BioMedReports is pumping it like crazy--> noticed that too!
about 34 days ago by abubnic
about 34 days ago by abubnic
Rodman & Renshaw Starts Neptune Technologies (NEPT) at Market Outperform
Apr 26, 9:37AM Street Insider
Apr 26, 9:37AM Street Insider
Equity Briefing: Exec hints at doubling revenues and a possible spin-off dividend for NEPT investors
Apr 25, 2:48PM Thomson Reuters ONE
Apr 25, 2:48PM Thomson Reuters ONE
Co-Founder of Biotech Powerhouse, ImClone Systems, Sees the Same Type of Potential at Neptune Subsidiary
Apr 02, 7:01AM Marketwire
Apr 02, 7:01AM Marketwire
Neptune Signs John Elway, NFL Hall-of-Famer, as Official Brand Ambassador
Mar 27, 8:00AM GlobeNewswire
Mar 27, 8:00AM GlobeNewswire
RT @mikeadd $AMRN - $NEPT/Omthera..most of these trials were done in India, Russia...need I say anymore.....flushthatturd!
about 67 days ago by nobody99
about 67 days ago by nobody99
Neptune Technologies & Bioressources Investing Over $20M in Sherbrooke
Mar 09, 10:00AM GlobeNewswire
Mar 09, 10:00AM GlobeNewswire
Acasti to Present at The Annual Roth Conference and Grants Incentive Stock Options
Mar 06, 8:00AM GlobeNewswire
Mar 06, 8:00AM GlobeNewswire
Acasti Pharma's (TSXV:APO) Dr. Harlan Waksal Interviewed by Grant Howard of Howard Group - Video Hosted on www.InvestmentPitch.com
Mar 02, 2:27PM Thomson Reuters ONE
Mar 02, 2:27PM Thomson Reuters ONE
Neptune Premium Krill Oil, NKO(R) Enters the Mass Market With Jamieson Laboratories, the Largest Brand in Canada
Feb 15, 8:00AM GlobeNewswire
Feb 15, 8:00AM GlobeNewswire
Acasti Pharma Announces a Private Placement Financing of Approximately $2,000,000 CDN
Feb 07, 11:52AM GlobeNewswire
Feb 07, 11:52AM GlobeNewswire
Neptune, Aker and Schiff Agree to Stay of Litigation During Patent Re-Examination Proceedings
Feb 02, 12:24PM GlobeNewswire
Feb 02, 12:24PM GlobeNewswire
$NEPT http://stks.co/1jcl Kumo break-out on volume, closed just above the cloud, 200 day overhead
about 150 days ago by Tr8r_x
about 150 days ago by Tr8r_x
$NEPT - Neptune’s Q3/F12 Guidance Calls For Record Revenue - $5-5.25 million http://stks.co/1LSV #krill #investing
about 181 days ago by HowardGroup
about 181 days ago by HowardGroup
$NEPT - Neptune Makes the Move to the TSX – Canada’s Senior Exchange http://stks.co/1GLz
about 188 days ago by HowardGroup
about 188 days ago by HowardGroup
$NEPT - Neptune – Dr. Oz says Krill Omega 3 is Superior to Fish Oil http://stks.co/1Fnj #DrOz
about 189 days ago by HowardGroup
about 189 days ago by HowardGroup
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| NEPT | 3.80 | +0.00 | +0.00% | 183.46M |
| NEP | 3.11 | +0.00 | +0.00% | 110.28M |
| NEOG | 38.47 | -0.09 | -0.23% | 907.32M |
| NEN | 27.00 | +0.00 | +0.00% | 85.32M |
| NEM | 47.85 | -0.33 | -0.68% | 23.62B |
| NEI | 0.80 | +0.01 | +1.27% | 33.61M |
| NEE | 65.15 | -0.49 | -0.75% | 27.32B |
| NEBS | 9.78 | -0.71 | -6.77% | 63.99M |
| NEA | 15.00 | -0.02 | -0.13% | |
| NE | 32.61 | -1.54 | -4.51% | 8.612B |
